GlassScriptPhysician profile
Robert J Meador
NPI 1891725396
$12,337.26
in general payments reported to CMS, 2019-2025
34 companies · $2,344 in 2025
The $2,344 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,721 · 2020: $751 · 2021: $1,151 · 2022: $1,833 · 2023: $2,315 · 2024: $2,223 · 2025: $2,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,395 · Consulting Fee: $295 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,394.53 |
| Consulting Fee | $295.00 |
| Education | $191.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,578.25 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Janssen Biotech, INC. | $1,286.72 | 2019-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $1,179.40 | 2019-2025 | |
| Pfizer INC. | $968.68 | 2019-2025 | |
| Glaxosmithkline, LLC. | $816.74 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $809.10 | 2019-2024 | Taltz, Olumiant |
| Ucb, INC. | $777.95 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $634.06 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $589.08 | 2021-2025 | Saphnelo |
| Ani Pharmaceuticals, INC. | $380.73 | 2024-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $297.67 | 2023-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.95 | 2020-2025 | Ofev, Cyltezo |
| Genentech USA, INC. | $243.07 | 2019-2025 | Actemra |
| Aurinia Pharma U.S., INC. | $231.77 | 2021-2024 | Lupkynis |
| Cardinal Health 110 LLC | $200.00 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $156.37 | 2019 | |
| Sandoz INC. | $150.07 | 2023-2025 | Hyrimoz |
| Genzyme Corporation | $116.52 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $110.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $84.98 | 2019-2025 | Orencia |
| Organon LLC | $70.93 | 2023-2025 | Hadlima, Renflexis |
| Sobi, INC | $50.93 | 2020-2025 | |
| Mallinckrodt Enterprises LLC | $48.81 | 2019 | |
| Horizon Therapeutics Plc | $40.88 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $40.41 | 2023-2024 | Keveyis |
| Tonix Medicines, INC. | $30.67 | 2025 | Tonmya |
| Merck Sharp & Dohme LLC | $29.09 | 2019 | |
| Ferring Pharmaceuticals INC. | $27.42 | 2025 | Rebyota |
| Csl Behring | $25.51 | 2025 | Hizentra |
| Pacira Therapeutics, INC. | $22.67 | 2019 | |
| Kyowa Kirin, INC. | $21.64 | 2024 | Crysvita |
| Alexion Pharmaceuticals, INC. | $20.70 | 2023 | Ultomiris |
| Kowa Pharmaceuticals America, INC. | $18.91 | 2022 | |
| Fidia Pharma USA INC. | $13.58 | 2024 | Hymovis, Triluron, Hyalgan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Meador listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.